Session Type: ePosters
Session Title: ePosters
Authors(s): S. Alosaimy (1), J. Bouchard (2), S.L. Kang-Birken (3), K.C. Molina (4), A.L. Hobbs (5), N.B. Perkins Iii (6), K.C. Claeys (7), M.A. King (8), B.M. Pullinger (8), M. Veve (1), S. Tart (9), M. Biagi (10), M. Pierce (10), L.M. Rojas (11), B.M. Jones (12), J. Truong (13), J. Andrade (13), R. Cosimi (14), G. Huang (15), A.M. Lagnf (1), T. Morrisette (1), D. Holger (1), N. Rebold (1), S.L. Davis L (1), M.J. Rybak (1)
Authors Affiliations(s): (1) Wayne State University, United States, (2) University of South Carolina, United States, (3) Santa Barbara Cottage Hospital, United States, (4) University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States, (5) Methodist University Hospital, United States, (6) University of Tennessee Health Science Center College of Pharmacy, United States, (7) University of Maryland School of Pharmacy, United States, (8) Philadelphia College of Pharmacy, United States, (9) Cape Fear Valley Health, United States, (10) SwedishAmerican Hospital, United States, (11) Valley Hospital Medical Center, United States, (12) St Joseph’s/Candler Health System,, United States, (13) The Brooklyn Hospital Center, United States, (14) Ascension St Vincent, United States, (15) University of California Los Angeles, United States
Background:
Eravacycline (ERV) is approved in the United States (US) for the treatment of complicated intra-abdominal infections in adults. Multicenter, real-world data regarding ERV use is limited. We evaluated the clinical/safety outcomes of patients treated with ERV for various infections.
Methods:This multicenter, retrospective, observational study was conducted from September,2018 to Janurary,2021. We included adults treated with ERV for =>72hours. The primary outcome was 30-day survival. Secondary outcomes were 30-day infection-recurrence, persistence of infection signs/symptoms, ERV-adverse events and reasons for utilization. All outcomes were measured from ERV start.
Results:Overall, 196 patients were included from 15 medical centers in 12 states geographically spread across the US. ERV was selected primarily for regimen consolidation (44.9%). The median (IQR) age was 61(50-70) years and (55.1%) were male. Median (IQR) APACHE II, SOFA, and Charlson Comorbidity scores were 14.0(9.5-20.5), 4.0(1.0-7.0), and 3.0(1.0-5.0), respectively. Intensive care admission occurred in 58.1%, and sources of infection were primarily of respiratory (26.0%) and intra-abdominal (25.0%) origin. Common pathogens were Acinetobacter baumannii (21.4%), with the majority being Carbapenem-resistant A. baumannii (24/42,57.1%), Enterococcus faecium (14.3%), Klebsiella pneumoniae and Staphylococcus aureus (13.8%, each). Among all Enterobacterales (n=68); (16/68, 23.5%) were Carbapenem-resistant Enterobacterales. Infectious diseases consultation and surgical interventions were obtained in (94.4%) and (53.1%), respectively. Patients often received active therapy (47.4%) prior to ERV, and (55.1%) received combination therapy with ERV =>48hours. Median (IQR) ERV therapy duration was 7(4-13) days. Among cases with documented cultures (n=172), ERV was initiated within a median (IQR) of 4(2-10) days of collection. Thirty-day survival occurred in 78.1%. Of patients who died (n=43), (83.7%) were critically ill, (34.9%) each had intra-abdominal or pneumonia as a source, and (20.9%) had positive blood cultures. For secondary outcomes, (6.1%) experienced 30-day infection-recurrence, (27.1%) experienced persistence of infection signs/symptoms, and (19.4%) switched to an alternative agent [primarily meropenem (18.4%). A probable ERV-related adverse event occurred in (10.7%) [primarily gastrointestinal (5.6%)], which led to discontinuation in (4.7%).
Conclusions:
ERV was associated with positive clinical outcomes and ERV-adverse events were uncommon and mostly gastrointestinal. Comparative studies with longer follow-up are required to assess the effectiveness and safety of ERV.
Keyword(s): eravacycline, Acinetobacter baumannii, EnterobacteralesCOI Institutional Grants: Yes
COI Other: Michael J Rybak has received research support, consultant or speaker for Allergan, Contrafect, Melinta, Merck, Motif, Paratek, Tetraphase, Shionogi, Spero and is partially supported by NIAID AI121400 and AI1300056-04.
Session Type: ePosters
Session Title: ePosters
Authors(s): S. Alosaimy (1), J. Bouchard (2), S.L. Kang-Birken (3), K.C. Molina (4), A.L. Hobbs (5), N.B. Perkins Iii (6), K.C. Claeys (7), M.A. King (8), B.M. Pullinger (8), M. Veve (1), S. Tart (9), M. Biagi (10), M. Pierce (10), L.M. Rojas (11), B.M. Jones (12), J. Truong (13), J. Andrade (13), R. Cosimi (14), G. Huang (15), A.M. Lagnf (1), T. Morrisette (1), D. Holger (1), N. Rebold (1), S.L. Davis L (1), M.J. Rybak (1)
Authors Affiliations(s): (1) Wayne State University, United States, (2) University of South Carolina, United States, (3) Santa Barbara Cottage Hospital, United States, (4) University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States, (5) Methodist University Hospital, United States, (6) University of Tennessee Health Science Center College of Pharmacy, United States, (7) University of Maryland School of Pharmacy, United States, (8) Philadelphia College of Pharmacy, United States, (9) Cape Fear Valley Health, United States, (10) SwedishAmerican Hospital, United States, (11) Valley Hospital Medical Center, United States, (12) St Joseph’s/Candler Health System,, United States, (13) The Brooklyn Hospital Center, United States, (14) Ascension St Vincent, United States, (15) University of California Los Angeles, United States
Background:
Eravacycline (ERV) is approved in the United States (US) for the treatment of complicated intra-abdominal infections in adults. Multicenter, real-world data regarding ERV use is limited. We evaluated the clinical/safety outcomes of patients treated with ERV for various infections.
Methods:This multicenter, retrospective, observational study was conducted from September,2018 to Janurary,2021. We included adults treated with ERV for =>72hours. The primary outcome was 30-day survival. Secondary outcomes were 30-day infection-recurrence, persistence of infection signs/symptoms, ERV-adverse events and reasons for utilization. All outcomes were measured from ERV start.
Results:Overall, 196 patients were included from 15 medical centers in 12 states geographically spread across the US. ERV was selected primarily for regimen consolidation (44.9%). The median (IQR) age was 61(50-70) years and (55.1%) were male. Median (IQR) APACHE II, SOFA, and Charlson Comorbidity scores were 14.0(9.5-20.5), 4.0(1.0-7.0), and 3.0(1.0-5.0), respectively. Intensive care admission occurred in 58.1%, and sources of infection were primarily of respiratory (26.0%) and intra-abdominal (25.0%) origin. Common pathogens were Acinetobacter baumannii (21.4%), with the majority being Carbapenem-resistant A. baumannii (24/42,57.1%), Enterococcus faecium (14.3%), Klebsiella pneumoniae and Staphylococcus aureus (13.8%, each). Among all Enterobacterales (n=68); (16/68, 23.5%) were Carbapenem-resistant Enterobacterales. Infectious diseases consultation and surgical interventions were obtained in (94.4%) and (53.1%), respectively. Patients often received active therapy (47.4%) prior to ERV, and (55.1%) received combination therapy with ERV =>48hours. Median (IQR) ERV therapy duration was 7(4-13) days. Among cases with documented cultures (n=172), ERV was initiated within a median (IQR) of 4(2-10) days of collection. Thirty-day survival occurred in 78.1%. Of patients who died (n=43), (83.7%) were critically ill, (34.9%) each had intra-abdominal or pneumonia as a source, and (20.9%) had positive blood cultures. For secondary outcomes, (6.1%) experienced 30-day infection-recurrence, (27.1%) experienced persistence of infection signs/symptoms, and (19.4%) switched to an alternative agent [primarily meropenem (18.4%). A probable ERV-related adverse event occurred in (10.7%) [primarily gastrointestinal (5.6%)], which led to discontinuation in (4.7%).
Conclusions:
ERV was associated with positive clinical outcomes and ERV-adverse events were uncommon and mostly gastrointestinal. Comparative studies with longer follow-up are required to assess the effectiveness and safety of ERV.
Keyword(s): eravacycline, Acinetobacter baumannii, EnterobacteralesCOI Institutional Grants: Yes
COI Other: Michael J Rybak has received research support, consultant or speaker for Allergan, Contrafect, Melinta, Merck, Motif, Paratek, Tetraphase, Shionogi, Spero and is partially supported by NIAID AI121400 and AI1300056-04.
Wayne State University
Session Type: ePosters
Session Title: ePosters
Authors(s): S. Alosaimy (1), J. Bouchard (2), S.L. Kang-Birken (3), K.C. Molina (4), A.L. Hobbs (5), N.B. Perkins Iii (6), K.C. Claeys (7), M.A. King (8), B.M. Pullinger (8), M. Veve (1), S. Tart (9), M. Biagi (10), M. Pierce (10), L.M. Rojas (11), B.M. Jones (12), J. Truong (13), J. Andrade (13), R. Cosimi (14), G. Huang (15), A.M. Lagnf (1), T. Morrisette (1), D. Holger (1), N. Rebold (1), S.L. Davis L (1), M.J. Rybak (1)
Authors Affiliations(s): (1) Wayne State University, United States, (2) University of South Carolina, United States, (3) Santa Barbara Cottage Hospital, United States, (4) University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States, (5) Methodist University Hospital, United States, (6) University of Tennessee Health Science Center College of Pharmacy, United States, (7) University of Maryland School of Pharmacy, United States, (8) Philadelphia College of Pharmacy, United States, (9) Cape Fear Valley Health, United States, (10) SwedishAmerican Hospital, United States, (11) Valley Hospital Medical Center, United States, (12) St Joseph’s/Candler Health System,, United States, (13) The Brooklyn Hospital Center, United States, (14) Ascension St Vincent, United States, (15) University of California Los Angeles, United States
Background:
Eravacycline (ERV) is approved in the United States (US) for the treatment of complicated intra-abdominal infections in adults. Multicenter, real-world data regarding ERV use is limited. We evaluated the clinical/safety outcomes of patients treated with ERV for various infections.
Methods:This multicenter, retrospective, observational study was conducted from September,2018 to Janurary,2021. We included adults treated with ERV for =>72hours. The primary outcome was 30-day survival. Secondary outcomes were 30-day infection-recurrence, persistence of infection signs/symptoms, ERV-adverse events and reasons for utilization. All outcomes were measured from ERV start.
Results:Overall, 196 patients were included from 15 medical centers in 12 states geographically spread across the US. ERV was selected primarily for regimen consolidation (44.9%). The median (IQR) age was 61(50-70) years and (55.1%) were male. Median (IQR) APACHE II, SOFA, and Charlson Comorbidity scores were 14.0(9.5-20.5), 4.0(1.0-7.0), and 3.0(1.0-5.0), respectively. Intensive care admission occurred in 58.1%, and sources of infection were primarily of respiratory (26.0%) and intra-abdominal (25.0%) origin. Common pathogens were Acinetobacter baumannii (21.4%), with the majority being Carbapenem-resistant A. baumannii (24/42,57.1%), Enterococcus faecium (14.3%), Klebsiella pneumoniae and Staphylococcus aureus (13.8%, each). Among all Enterobacterales (n=68); (16/68, 23.5%) were Carbapenem-resistant Enterobacterales. Infectious diseases consultation and surgical interventions were obtained in (94.4%) and (53.1%), respectively. Patients often received active therapy (47.4%) prior to ERV, and (55.1%) received combination therapy with ERV =>48hours. Median (IQR) ERV therapy duration was 7(4-13) days. Among cases with documented cultures (n=172), ERV was initiated within a median (IQR) of 4(2-10) days of collection. Thirty-day survival occurred in 78.1%. Of patients who died (n=43), (83.7%) were critically ill, (34.9%) each had intra-abdominal or pneumonia as a source, and (20.9%) had positive blood cultures. For secondary outcomes, (6.1%) experienced 30-day infection-recurrence, (27.1%) experienced persistence of infection signs/symptoms, and (19.4%) switched to an alternative agent [primarily meropenem (18.4%). A probable ERV-related adverse event occurred in (10.7%) [primarily gastrointestinal (5.6%)], which led to discontinuation in (4.7%).
Conclusions:
ERV was associated with positive clinical outcomes and ERV-adverse events were uncommon and mostly gastrointestinal. Comparative studies with longer follow-up are required to assess the effectiveness and safety of ERV.
Keyword(s): eravacycline, Acinetobacter baumannii, EnterobacteralesCOI Institutional Grants: Yes
COI Other: Michael J Rybak has received research support, consultant or speaker for Allergan, Contrafect, Melinta, Merck, Motif, Paratek, Tetraphase, Shionogi, Spero and is partially supported by NIAID AI121400 and AI1300056-04.
Session Type: ePosters
Session Title: ePosters
Authors(s): S. Alosaimy (1), J. Bouchard (2), S.L. Kang-Birken (3), K.C. Molina (4), A.L. Hobbs (5), N.B. Perkins Iii (6), K.C. Claeys (7), M.A. King (8), B.M. Pullinger (8), M. Veve (1), S. Tart (9), M. Biagi (10), M. Pierce (10), L.M. Rojas (11), B.M. Jones (12), J. Truong (13), J. Andrade (13), R. Cosimi (14), G. Huang (15), A.M. Lagnf (1), T. Morrisette (1), D. Holger (1), N. Rebold (1), S.L. Davis L (1), M.J. Rybak (1)
Authors Affiliations(s): (1) Wayne State University, United States, (2) University of South Carolina, United States, (3) Santa Barbara Cottage Hospital, United States, (4) University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States, (5) Methodist University Hospital, United States, (6) University of Tennessee Health Science Center College of Pharmacy, United States, (7) University of Maryland School of Pharmacy, United States, (8) Philadelphia College of Pharmacy, United States, (9) Cape Fear Valley Health, United States, (10) SwedishAmerican Hospital, United States, (11) Valley Hospital Medical Center, United States, (12) St Joseph’s/Candler Health System,, United States, (13) The Brooklyn Hospital Center, United States, (14) Ascension St Vincent, United States, (15) University of California Los Angeles, United States
Background:
Eravacycline (ERV) is approved in the United States (US) for the treatment of complicated intra-abdominal infections in adults. Multicenter, real-world data regarding ERV use is limited. We evaluated the clinical/safety outcomes of patients treated with ERV for various infections.
Methods:This multicenter, retrospective, observational study was conducted from September,2018 to Janurary,2021. We included adults treated with ERV for =>72hours. The primary outcome was 30-day survival. Secondary outcomes were 30-day infection-recurrence, persistence of infection signs/symptoms, ERV-adverse events and reasons for utilization. All outcomes were measured from ERV start.
Results:Overall, 196 patients were included from 15 medical centers in 12 states geographically spread across the US. ERV was selected primarily for regimen consolidation (44.9%). The median (IQR) age was 61(50-70) years and (55.1%) were male. Median (IQR) APACHE II, SOFA, and Charlson Comorbidity scores were 14.0(9.5-20.5), 4.0(1.0-7.0), and 3.0(1.0-5.0), respectively. Intensive care admission occurred in 58.1%, and sources of infection were primarily of respiratory (26.0%) and intra-abdominal (25.0%) origin. Common pathogens were Acinetobacter baumannii (21.4%), with the majority being Carbapenem-resistant A. baumannii (24/42,57.1%), Enterococcus faecium (14.3%), Klebsiella pneumoniae and Staphylococcus aureus (13.8%, each). Among all Enterobacterales (n=68); (16/68, 23.5%) were Carbapenem-resistant Enterobacterales. Infectious diseases consultation and surgical interventions were obtained in (94.4%) and (53.1%), respectively. Patients often received active therapy (47.4%) prior to ERV, and (55.1%) received combination therapy with ERV =>48hours. Median (IQR) ERV therapy duration was 7(4-13) days. Among cases with documented cultures (n=172), ERV was initiated within a median (IQR) of 4(2-10) days of collection. Thirty-day survival occurred in 78.1%. Of patients who died (n=43), (83.7%) were critically ill, (34.9%) each had intra-abdominal or pneumonia as a source, and (20.9%) had positive blood cultures. For secondary outcomes, (6.1%) experienced 30-day infection-recurrence, (27.1%) experienced persistence of infection signs/symptoms, and (19.4%) switched to an alternative agent [primarily meropenem (18.4%). A probable ERV-related adverse event occurred in (10.7%) [primarily gastrointestinal (5.6%)], which led to discontinuation in (4.7%).
Conclusions:
ERV was associated with positive clinical outcomes and ERV-adverse events were uncommon and mostly gastrointestinal. Comparative studies with longer follow-up are required to assess the effectiveness and safety of ERV.
Keyword(s): eravacycline, Acinetobacter baumannii, EnterobacteralesCOI Institutional Grants: Yes
COI Other: Michael J Rybak has received research support, consultant or speaker for Allergan, Contrafect, Melinta, Merck, Motif, Paratek, Tetraphase, Shionogi, Spero and is partially supported by NIAID AI121400 and AI1300056-04.